

IMMUNO-ONCOLOGY SOCIETY OF INDIA

# 3<sup>rd</sup> Annual Congress 2021



**8<sup>TH</sup> - 10<sup>TH</sup>**  
OCTOBER, 2021



**"Precision Immuno-Oncology :  
Choosing wisely"**



**I-OSI Virtual Congress**

**Participants will get CME credit points**

## Organizers



**Prof. Dr. Atul Sharma**  
AIIMS, New Delhi



**Prof. Dr. Jyoti Bajpai**  
TMC, Mumbai



**Dr. Amit Awasthi**  
THSTI, Faridabad

**Registration Link :**

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveerroute**  
Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

Dear Colleagues,

On behalf of Immuno-oncology Society of India, we are pleased to invite you for the **3<sup>rd</sup> Annual Congress of I-OSI**. This meeting will be held virtually from **8<sup>th</sup> - 9<sup>th</sup> October 2021 ( from 4pm - 9pm IST) & 10<sup>th</sup> October 2021 (from 9am - 2pm IST)**.

The theme of this year's conference is **"Precision Immuno-Oncology : Choosing wisely"**.

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them. According to the report, there was a 22 percent increase of I-O drugs in the development pipeline from 2019 to 2020. Overall, this growth amounts to a 233 percent increase from the first CRI I-O Landscape report published just three years ago.

At this conference, Immuno-oncology International and National expert will provide up-to-date data insights supporting the use of precision immunotherapies, including immune checkpoint inhibitors, cellular therapies, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions.

I-OSI is committed to continuously deliver top-notch content and bring all experts under the same roof. There will be an Online Preparatory Workshop which is aimed to warm up the conference audience prior to the main conference. This conference will help connect academics, industry experts, and professionals interested in IO. Keynote lectures, engaging panels and ample time for audience Q&A are regular feature of I-OSI events.

The organising committee wishes to start connecting with all the oncologists to kick-start the discussion and help build a more inclusive and engaging I-OSICON 2021.

We look forward to making this a great learning opportunity for all participants.

Regards,

## Dr. Atul Sharma

Professor, Department of Medical Oncology,  
Dr. BRA Institute-Rotary Cancer Hospital,  
All India Institute of Medical Science,  
New Delhi

## Dr. Amit Awasthi

Associate Professor, Translational Health  
Science & Technology Institute,  
An Autonomous Institute of Department of  
Biotechnology, Ministry of Science & Technology,  
Govt of India, New Delhi

## Dr. Jyoti Bajpai

Professor, Department of Medical Oncology,  
Tata Memorial Center and Homi Bhabha National Institute,  
Founder General Secretary - Immuno-Oncology Society of India  
ESMO faculty for Investigational Immunotherapy  
ESMO W40- core committee member  
Founder Chair W40-India (under ISMPO), Mumbai

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## ORATION SPEAKER



### Dr. Tasuku Honjo

#### Nobel Laureate

Deputy Director General and Distinguished Professor,  
Department of Immunology and Genomic Medicine Kyoto  
University Faculty of Medicine,  
Executive Member,  
The Council for Science and Technology Policy Cabinet Office  
Kyoto, Japan

**Prof. Tasuku Honjo**, is a Japanese immunologist who contributed to the discovery of mechanisms and proteins critical to the regulation of immune responses and whose work led to the development of novel immunotherapies against cancer. Prof. Honjo was recognized for his work with the 2018 Nobel Prize for Physiology or Medicine, which he shared with American immunologist James P. Allison.

Prof. Honjo studied medicine at Kyoto University, graduating with an M.D. in 1966. He later also received a Ph.D. (1975) in medical chemistry from there. While a graduate student, he received fellowships to study at the Carnegie Institution for Science and the U. S. National Institutes of Health, where he carried out research on the immune response. In 1974, after returning to Japan, Prof. Honjo joined the faculty of medicine at the University of Tokyo and in 1979 moved to the Osaka University School of Medicine, where he became a professor in the department of genetics. At Osaka, Honjo elucidated the mechanism of immunoglobulin class switching (class-switch recombination), whereby B cells switch their antibody production from one antibody type to another depending on the type of antigen with which they are presented.

In 1984 Prof. Honjo returned to Kyoto University, where he joined the department of medical chemistry. There, in the 1990s, he and colleagues discovered a protein called programmed cell death protein 1 (PD-1) on the surface of T cells. In later experiments, Honjo and colleagues deduced the function of PD-1 as a negative regulator of immune responses and found that PD-1 deficiency played a critical role in the development of lupus-like autoimmune diseases. In the early 2000s, Honjo showed that PD-1 inhibition in animal models of cancer restored the ability of T cells to target and kill cancer cells. Prof. Honjo's findings opened the way for the development of anti-PD-1 cancer immunotherapies, including nivolumab and pembrolizumab, which were approved for the treatment of melanoma and certain other cancers. From 2005 Honjo was a professor in the immunology and genomic medicine department at Kyoto.

Registration Link :


<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Prof. Solange Peters

Chair Medical Oncology  
Oncology Department – CHUV  
Lausanne University, Switzerland  
ESMO President, Scientific Coordinator,  
European Thoracic Oncology Platform (ETOP),  
JTO Deputy Editor

**Prof. Solange Peters** is the Head of the Medical Oncology Service and Chair of Thoracic Oncology, Oncology Department at the Lausanne University Hospital, Switzerland. She has been announced as the President of the Society for the 2020–2021 term by the European Society for Medical Oncology (ESMO).

Prof. Peters is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan in Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute.

Prof. Peters' main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally-advanced NSCLC as well as clinical and translational cancer immunotherapy. Her current research projects as a chair are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy for the treatment of NSCLC, SCLC, thymic malignancies and mesothelioma, denosumab in advanced NSCLC, ALK, RET, EGFR as well HER2 inhibitors. She acts as the local Principal Investigator (PI) of lung trials opened in Lausanne Cancer Centre. In addition, she is a Co-PI of several other trials.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveroute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Prof. Silvia Stacchiotti

Department of Medical Oncology  
IRCCS Foundation, National Cancer Institute,  
Milan, Italy

**Prof. Silvia Stacchiotti** is a medical oncologist works in the Adult Mesenchymal and Rare Tumor Medical Treatment Unit, Cancer Medicine Department, IRCCS Foundation, National Cancer Institute, Milan, Italy.

Dr. Silvia Stacchiotti received her medical degree in 1993 in Milan, and trained at the INT. She is board certified in Medical Oncology.

She is involved in all institutional research activities on adult bone and soft tissue sarcomas (STS), including GIST. This includes neoadjuvant therapies in extremities and retroperitoneal STS, identification of new targets and new anticancer treatments for specific sarcoma types, studies on the immune-profile of sarcomas as well as on mechanisms of resistance to therapy and the development of preclinical models of sarcomas. She collaborates to the Italian Network on Rare Tumors. She is particularly dedicated to ultra-rare sarcomas, among which chordoma, chondrosarcoma, giant cell tumor of the bone, extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell sarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, PEComa, vascular tumors, epithelioid sarcoma, desmoid tumor, tenosynovial giant cell tumor. She is the Principal Investigator of several Italian and International trials on sarcomas. She is the current president of the Italian Sarcoma Group (ISG). She is the faculty coordinator of the Sarcoma track of the European Society for Medical Oncology (ESMO) and the subject editor of the ESMO guidelines committee for sarcoma and GIST. She is a member of the Board of Directors of the Connective Tissue Oncology Society (CTOS). She is included in the list of European Medical Agency (EMA) external experts. She is the chair of the systemic therapy subcommittee of the EORTC Soft Tissue and Bone Sarcoma Group. She collaborates with several sarcoma Patients Advocacy Groups, among which the Chordoma Foundation, the Desmoid Tumor Research Foundation, the EHE Foundation, in which she serves as a member of the respective medical advisory boards.

She has authored more than 200 scientific publications (scopus HI 51). She serves on the editorial board of European Journal of Cancer and Cancer.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA

# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## ORATION SPEAKER



### Dr. John B. Haanen

Head of the Division of Medical Oncology and Staff Scientist, Division of Immunology, Professor of Translational Immunotherapy of Cancer, Leiden University Medical Centre, The Netherlands

**Dr. John Haanen** finished his MD at Leiden University cum laude in 1988. From 1988 till 1991 he performed his PhD studies at the Division of Immunohematology & Blood Bank of Leiden University Medical Center and at DNAX, Research Institute, Palo Alto, California, US and defended his PhD thesis on human CD4+ helper T cells reactive against mycobacteria. He trained in internal medicine in hospitals in Leiden and The Hague. In 1996 he was registered as consultant internist. From 1997-1999 he did a post-doctoral fellowship at the Division of Immunology of the Netherlands Cancer Institute (NKI), Amsterdam. From 1999-2001 he trained in medical oncology and was appointed a permanent position as consultant medical oncologist and research group leader at NKI. His research has been focused on development of innovative immunotherapies in close collaboration with prof. Ton Schumacher. In 2008 he was appointed professor of translational immunotherapy of cancer at Leiden University Medical Center. From 2009 till 2018 he headed the Division of Medical Oncology at NKI. In 2018 he was appointed CSO Immunotherapy, one of the major research themes at NKI. His current research is on development of cellular therapies for solid tumors, neoadjuvant immunotherapies, and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer and management of immune-related adverse events. He coauthored over 300 peer-reviewed articles, serves at the editorial board of ESMO Open, Cancer Treatment Reviews and Kidney Cancer. He is currently Editor-in-Chief of ESMO IOTECH. Dr. John Haanen was scientific co-chair of ESMO IO Congress from 2016-2019, and Scientific Chair of the ESMO 2020 Congress.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Michael A. Postow

Consultant Medical Oncologist,  
Chief, Melanoma Service,  
Memorial Sloan Kettering Cancer Center,  
New York, USA

**Dr. Michael Postow** is a physician on faculty at Memorial Sloan Kettering Cancer Center in the Melanoma and Immunotherapeutics Oncology Service. He completed medical school at New York University School of Medicine and internal medicine residency training at Brigham and Women's Hospital/Harvard Medical School. He then returned to New York City to pursue a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center where he conducts clinical research with Dr. Jedd Wolchok in melanoma and immunotherapy. He has led clinical trials involving immunotherapeutic agents, most notably a phase II study of the combination of nivolumab and ipilimumab and investigations into the combination of radiotherapy and immunotherapy. His translational efforts involve studying immunologic biomarkers associated with response to immune checkpoint inhibition. He is the Editor-In-Chief for the journal, Clinical Skin Cancer, and he also serves on the editorial board of the Journal for the Immunotherapy of Cancer.

Registration Link :  
<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by  
**rive2route**  
Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA

# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. James Larkin

Consultant Medical Oncologist,  
The Royal Marsden, NHS Foundation Trust,  
London, UK

**Prof. James Larkin** is a Medical Oncologist specializing in the treatment of melanoma and cancers of the kidney.

Professor Larkin grew up in North Cornwall before taking a first in Natural Sciences from Cambridge University. He undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.

His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.

He is a past Senior Clinical Advisor to CRUK, National Institute for Health Research (NIHR) National Specialty Lead for Early Phase Oncology Trials, as well as past Chair of the NCRI Renal Cancer Clinical Studies Group, The Royal Marsden/ICR Committee for Clinical Research and the CRUK Clinical Research Monitoring Panel. He is currently Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/ICR Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences. Since 2019 he has been Vice Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board and in 2020 he was appointed as an NIHR Senior Investigator.

He serves as a medical advisor to the patient advocacy group Melanoma UK, as a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Ravindran Kanesvaran

Deputy Chair & Senior Consultant,  
Division of Medical Oncology,  
National Cancer Centre,  
Singapore

**Assoc. Prof. Ravindran Kanesvaran** is the Deputy Chair and Senior Consultant in the Division of Medical Oncology of the National Cancer Centre Singapore. He is also an Associate Professor at Duke-NUS Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is the Program Director of the Medical Oncology Senior Residency Program. His research interests include GU oncology and geriatric oncology. He has published in well-known peer reviewed journals including Journal of Clinical Oncology and Lancet Oncology. He is the author of several textbook chapters in Geriatric Oncology.

He has been awarded the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society for Medical Oncology (ESMO) fellowship award 2012. He is currently the Immediate Past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is the President and of the International Society of Geriatric Oncology (SIOG) and was awarded National Representative of the Year SIOG 2014 award. He is also the Vice Chairman of the Singapore Cancer Society (SCS) and Council Member of the European Society of Medical Oncology (ESMO).

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveroute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Lynda Chin

Chief Executive Officer,  
Apricity Health LLC,  
Houston, Texas, United States

**Dr. Chin** is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, analytics and data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of the Department of Genomic Medicine at MD Anderson, and later as Chief Innovation Officer of the University of Texas System, Dr. Chin had developed technology-enabled platforms to facilitate the translation of genomic science and analytic insights into the practice of medicine. Throughout her career, Dr. Chin has also been a champion for cross-industry collaboration. As the scientific director at the Belfer Applied Cancer Institute of Dana-Farber Cancer Institute and later at the Institute for Applied Cancer Science of MD Anderson Cancer Center, Dr. Chin has developed novel organizational construct to bridge across academia and industry to accelerate science-based drug discovery. Forseeing the paradigm shift in research and care driven by data and technologies, Dr. Chin founded Apricity Health, a digital medicine company that brings together technologies and real-world data with science and clinical expertise to transform cancer care and therapeutic development.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Nina Shah

Consultant Hematologist-Oncologist,  
University of California, San Francisco,  
USA

**Dr. Nina Shah** is a Professor of Clinical Medicine in the Division of Hematology-Oncology at University of California San Francisco. Her research focuses on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She performed the first-in-human clinical trial of umbilical cord blood-derived natural killer cell therapy for myeloma and is one of the lead principal investigators for the multi-center BMT CTN 1401 dendritic cell vaccine trial for myeloma patients. Additionally, she is the institutional PI for numerous cellular therapy and immunotherapy protocols.

Dr. Shah is also interested in outcomes research for myeloma patients undergoing autologous transplantation and led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. She has published on the link between patient reported outcomes and physical testing in this clinical context and is conducting a study to investigate digital life coaching during transplant recovery. She is heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Blood and Marrow Transplant (ASBMT). She also serves as a Co-Chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a member of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Nora Disis

Helen B. Slonaker Endowed Professor for Cancer Research  
University of Washington (UW) Associate Dean for  
Translational Health Sciences UW School of Medicine Seattle,  
WA

**Dr. Disis** is the Helen B. Slonaker Endowed Professor for Cancer Research at the University of Washington (UW), Associate Dean for Translational Health Sciences in the UW School of Medicine, Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at UW and a Member of the Fred Hutchinson Cancer Research Center. She is the Director of UW Medicine's Cancer Vaccine Institute. Her research interest is in the discovery of new molecular immunologic targets in solid tumors for the development of vaccine and cellular therapy for the treatment and prevention of common malignancies. In addition, her group evaluates the use of the immune system to aid in the diagnosis of cancer and develops novel assays and approaches to quantitate and characterize human immunity. She holds several patents in the field of targeted cancer immunotherapy and immune-based diagnostics. Dr. Disis is a member of the American Society of Clinical Investigation and the Association of American Physicians. She holds a leadership award from the Komen for the Cure Foundation and is an American Cancer Society Clinical Professor. Dr. Disis is the Editor-in-Chief of JAMA Oncology.

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA

# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## KEYNOTE SPEAKER



### Dr. Vijay Kuchroo

Samuel L. Wasserstrom Professor of Neurology, Harvard Medical School, Senior Scientist, Brigham and Women's Hospital, and Co-Director, Center for Infection and Immunity, Brigham Research Institutes, Boston, USA

**Dr. Vijay Kuchroo** is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital. His major research interests include autoimmune diseases - particularly the role of co-stimulation - the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis. His laboratory also first described TIM family of genes and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of a highly pathogenic Th17 cells which has been shown to induce multiple different autoimmune diseases in humans. A paper describing development of Th17 authored by Dr. Kuchroo has been one of the highest cited papers in Immunology.

Dr. Kuchroo came to the United States in 1985 and was at the National Institutes of Health, Bethesda as Fogarty International Fellow for a year before joining the department of pathology at Harvard Medical School as a research fellow. He later joined the Center for Neurologic Diseases at Brigham and Women's Hospital as a junior faculty member in 1992.

He obtained his degree in Veterinary Medicine from the College of veterinary medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane (Australia) where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research prize and medal for his Ph.D. research work. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly lecturer in 2014, Garber Lecturer by the French Society of Immunology in 2014 and was recipient of Nobel Laureate Peter Doherty lecture/prize in 2014. In 2019, he was the recipient of the Milestones in Research Award by the National Multiple Sclerosis Society, New York. He was also awarded 2020 ICIS-Biolegend William E. Paul Award by the International Cytokine and Interferon Society for his role in discovery of Th17 cells.

Dr. Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals, Potenza Pharmaceuticals, Tizona Pharmaceuticals and Celsius pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including Biocon, Syngene, Sanofi, Pfizer, Novartis and Glaxo-Smith-Klein (GSK).

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveRoute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## SCIENTIFIC PROGRAM | FRIDAY, 08<sup>TH</sup> OCTOBER, DAY 1

Time (IST)	Topic
16:00 - 16:10	Opening remarks
16:10 - 16:15	<b>Chairpersons : Dr. Vineet Talwar, Dr. T B Yuvaraja</b>
16:15 - 16:40	Recent updates of immunotherapy in urinary bladder cancer with special emphasis on sequencing and extremes of age <b>Speaker : Dr. Ravindran Kanesvaran</b>
16:40 - 16:50	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Vikas Talreja</b>
16:50 - 17:10	<b>Inauguration &amp; Society Oration</b>
17:10 - 17:15	<b>Chairpersons : Dr. R A Badwe, Dr. Randeep Guleria, Dr. Pramod Garg</b>
17:15 - 17:50	<b>Future Perspective of Cancer Immunotherapy</b> <b>Speaker : Dr. Tasuku Honjo</b>
17:50 - 18:00	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Amit Awasthi</b>
18:00 - 18:15	<b>Break</b>
18:15 - 18:20	<b>Chairpersons : Dr. Shyam Aggarwal, Dr. Manish Agarwal</b>
18:20 - 18:45	<b>History of immunotherapy in sarcomas and newer advancements in the field</b> <b>Speaker : Dr. Silvia Stacchiotti</b>
18:45 - 18:55	<b>Q &amp; A with Lead Discussant</b> <b>Lead Discussant : Dr. Venkatraman Radhakrishnan</b>
18:55 - 19:00	<b>Chairpersons : Dr. Raghunadharao D, Dr. Hemant Tongaonkar</b>
19:00 - 19:25	<b>Recent advances in immunotherapy of Renal Cell Carcinoma</b> <b>Speaker : Dr. James Larkin</b>
19:25 - 19:35	<b>Q &amp; A with Lead Discussant</b> <b>Lead Discussant : Dr. Ashish Singh</b>

**Registration Link :**  
<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by  
**rive2route**  
Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## SCIENTIFIC PROGRAM | FRIDAY, 08<sup>TH</sup> OCTOBER, DAY 1

Time (IST)	Topic
19:35 - 19:40	<b>Chairpersons : Dr. S H Advani, Dr. Manjunath Shenoy</b>
19:40 - 20:05	<b>Two decades of advancements of melanoma from nihilism to optimism</b> <b>Speaker : Dr. Micheal A. Postow</b>
20:05 - 20:15	<b>Q &amp; A</b> <b>Lead Discussant : Bharath Rangarajan</b>
	<b>Chairpersons : Dr. Govind Babu, Dr. S D Banavali</b>
20-15 - 21:00	<b>Panel discussion: Management of toxicities</b> <b>Moderator : Dr. Jyoti Bajpai</b> <b>Panelists : Dr. Ravindran Kanesvaran,</b> <b>Dr. Silvia Stacchiotti, Dr. Micheal Postow,</b> <b>Dr. Chetan Deshmukh, Dr. Amit Rauthan,</b> <b>Dr. Amish Vora, Dr. John Haanen,</b> <b>Dr. Solange Peters</b>



Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveroute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October, 2021

## SCIENTIFIC PROGRAM | SATURDAY, 09<sup>TH</sup> OCTOBER, DAY 2

Time (IST)	Topic
16:00 - 16:05	Chairpersons : Dr. Pankaj Chaturvedi, Dr. D C Doval
16:05 - 16:20	Advancement in Immunotherapy of head and neck cancer Speaker : Dr. Kumar Prabhash
16:20 - 16:30	Q & A Lead Discussant : Dr. Raja Pramanik
16:30 - 16:35	Chairpersons : Dr. Sanjay Dudhat, Dr. Ramesh Nimmagadda
16:35 - 17:00	Role of TIM-3 in regulating anti-tumor immunity Speaker : Dr. Vijay Kuchroo
17:00 - 17:10	Q & A Lead Discussant : Dr. Prafulla Tailor
17:10 - 17:15	Chairpersons : Dr. Rajesh Mistry, Dr. Pankaj Shah
17:15 - 17:40	Immunotherapy of lung cancer- The paradigm shift from palliative to curative setting Speaker : Dr. Solange Peters
17:40 - 17:50	Q & A Lead Discussant : Dr. Ullas Batra
17:50 - 17:55	Chairperson : Dr. Amit Dutt, Dr. Anil D'cruz
17:55 - 18:20	AI and Big Data in cancer Speaker : Dr. Lynda Chin
18:20 - 18:30	Q & A Lead Discussant : Dr. Manish Singhal
	Presidential Oration
18:30 - 18:35	Chairpersons: Dr. Shubhada Chiplunkar, Dr. Rakesh Jalali
18:35 - 19:10	Precision IO by targeting neoantigens Speaker : Dr. John Haanen
19:10 - 19:20	Q & A Lead Discussant : Dr. Nitesh Rohatgi

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveroute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## SCIENTIFIC PROGRAM | SATURDAY, 09<sup>TH</sup> OCTOBER, DAY 2

Time (IST)	Topic
19:20 - 19:25	Chairpersons : Dr. SVS Deo, Dr. Hemant Malhotra
19:25 - 19:40	Immunotherapy in TNBC: Finally making an impact Speaker : Dr. Shona Nag
19:40 - 19:50	Q & A Lead Discussant : Dr. Padmaj Kulkarni
	Chairpersons : Dr. A F M Kamal Uddin, Dr. Sadashivudu Gundeti
19:50 - 20:35	Panel discussion- Advancement in IO and applicability in Indian context Moderator : Dr. Senthil Rajappa Panelists : Dr. Sudeep Gupta, Dr. Bhawna Sirohi, Dr. Navneet Singh, Dr. B K Smruti, Dr. Suresh Babu, Dr. T P Sahoo, Dr. Ashish Bakshi, Dr. Amit Agarwal



Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**riveroute**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## SCIENTIFIC PROGRAM | SUNDAY, 10<sup>TH</sup> OCTOBER, DAY 3

Time (IST)	Topic
09:00 - 09:05	<b>Chairperson : Dr. Dipankar Nandi, Dr. Sharmila Bapat</b>
09:05 - 09:30	<b>Vaccines targeting oncogenic pathways for cancer treatment and prevention</b> <b>Speaker : Dr. Nora Disis</b>
09:30 - 09:40	<b>Q &amp; A</b> <b>Lead Discussant : Dr. T Raja</b>
09:40 - 09:45	<b>Chairpersons : Dr. Tapan Saikia, Dr. Vikram Mathews</b>
09:45 - 10:10	<b>Emerging role of cellular therapies in management of multiple myeloma</b> <b>Speaker : Dr. Nina Shah</b>
10:10 - 10:20	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Bhausahab Bagal</b>
10:20 - 10:25	<b>Chairpersons : Dr. Vinod Raina, Dr. Shailesh Shrikhande</b>
10:25 - 10:40	<b>Advancement in Immunotherapy of gastrointestinal cancer</b> <b>Speaker : Dr. Atul Sharma</b>
10:40 - 10:50	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Prashant Mehta</b>
10:50 - 10:55	<b>Chairperson : Dr. Ahmed Ijaz Masood, Dr. Bharat Rekhi</b>
10:55 - 11:10	<b>Robust tumor immunity by high dietary salt is dependent on NK cells and gut microbiota</b> <b>Speaker : Dr. Zaigham Abbas Rizvi</b>
11:10 - 11:25	<b>I-OSI Indian Data</b> <b>Speaker : Dr. George Abraham</b>
11:25 - 11:35	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Prasanth Ganesan</b>

Registration Link :

<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by

**rive2route**

Leaders in Streaming Modules





IMMUNO-ONCOLOGY SOCIETY OF INDIA



# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

## SCIENTIFIC PROGRAM | SUNDAY, 10<sup>TH</sup> OCTOBER, DAY 3

Time (IST)	Topic
11:35 - 11:40	<b>Chairperson : Dr. Santosh Chauhan, Dr. Prakash Chitalkar</b>
11:40 - 11:55	<b>CAR-T cells current status &amp; future in India</b> <b>Speaker : Dr. Rahul Purwar</b>
11:55 - 12:10	<b>Cellular therapies beyond CAR-T and applicability in India</b> <b>Speaker : Dr. Vikram Mathews</b>
12:10 - 12:20	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Vivek Radhakrishnan</b>
12:20 - 12:25	<b>Chairpersons : Dr. NK Mehra, Dr. Sunil Arora</b>
12:25 - 12:40	<b>Current status of Immuno oncology research in India - challenges and Remedies</b> <b>Speaker : Dr. Girdhari Lal</b>
12:40 - 12:50	<b>Q &amp; A</b> <b>Lead Discussant : Dr. Sandeep Singh</b>
12:50 - 13:35	<b>Chairpersons : Dr. Sumit Gujral, Dr. Reena Nair</b> <b>Panel Discussion- Advancement in Hematolymphoid malignancies with respect to immunotherapy</b> <b>Panel discussion- Advancement in IO and applicability in Indian context</b> <b>Moderator : Dr. Manju Sengar</b> <b>Panelists : Dr. Smita Kayal, Dr. Vipul Sheth, Dr. Sameer Bakhshi, Dr. Lingaraj Nayak, Dr. Hemant Malhotra, Dr. Hari Menon, Dr. Gaurav Narula, Dr. Preetesh Jain, Dr. Lalit Kumar</b>

**Registration Link :**  
<https://www.immunooncologyindia.com/iosi3>

Virtual event managed by  
**rive2route**  
Leaders in Streaming Modules







IMMUNO-ONCOLOGY SOCIETY OF INDIA

# 3<sup>rd</sup> Annual Congress 2021



08<sup>th</sup> – 10<sup>th</sup> October , 2021

BECOME I-OSI MEMBER

[www.immunooncologyindia.com/join-iosi](http://www.immunooncologyindia.com/join-iosi)

Register for 3<sup>rd</sup> IOSI Congress 2021

[www.immunooncologyindia.com/iosi3](http://www.immunooncologyindia.com/iosi3)

VIRTUAL CONGRESS MANAGED BY

**riveroute**<sup>®</sup>

Leaders in Streaming Modules

**Sachin Shahane**

Conference Manager,

3<sup>rd</sup> I-OSI Congress 2021

River Route Event, Mumbai

Mobile: +91 9890909494 | E-mail : [rrcg.sachin95@gmail.com](mailto:rrcg.sachin95@gmail.com)

Ground Floor, Ganesh Building, Adhyaru Industrial Estate,

Lower Parel (W), Mumbai - 400 013

